Overview
Oral Gemifloxacin Versus Intravenous Cefotaxime in Treatment of Spontaneous Bacterial Peritonitis
Status:
Recruiting
Recruiting
Trial end date:
2028-12-30
2028-12-30
Target enrollment:
0
0
Participant gender:
All
All
Summary
oral Gemifloxacin versus intravenous Cefotaxime in treatment of spontaneous bacterial peritonitisPhase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Tanta UniversityTreatments:
Cefotaxime
Cefoxitin
Gemifloxacin
Criteria
Inclusion Criteria:- Patients with spontaneous bacterial peritonitis
Exclusion Criteria:
- secondary peritonitis